How MAPS Came to Study MDMA for PTSD
MAPS, the organization I'm part of, decided to focus on MDMA, and that decision came out of a long look at the record. We built up a thorough review of the research, going all the way back to the earliest uses of MDMA and running right up to the present. What we have is close to a complete library of every study ever conducted on it. From all that material, a few patterns stood out, not to me personally but to Rick Doblin, who founded the organization and had been watching these things for years.
Two findings kept recurring. MDMA seemed helpful in working through trauma, and it seemed to open people up to one another in their relationships. That picture came from the accounts people had shared and from research outside of formal clinical settings. So Rick asked himself a practical question: what is the most pressing problem we could aim this at?
Post-traumatic stress disorder was one answer. It's widespread here, and roughly a third of people with treatment-resistant PTSD simply don't improve under the therapies available now. Anyone following the news knows the scale of it among veterans. About 20% of those returning from Afghanistan and Iraq carry a PTSD diagnosis, and the veteran suicide rate has been running at something like 20 a day. That's not a small gap to leave open. It demands a response.
Rick sat down with Michael Mithoefer and Annie Mithoefer, and in one of those classic getting-it-off-the-ground moments (the kind people describe as scribbling on a napkin, though it may have been a pad of paper), they sketched the plan. How would you take MDMA and turn it into a treatment for PTSD? What clinical trials would you need, and in what order? How do you get something approved, and how do you work with the DEA, the FDA, the institutional review boards, all the machinery that stands between a compound and the market?
Rick had already set up MAPS as a nonprofit before this, and he saw that structure as the vehicle for bringing MDMA back as a prescription medicine. That route felt like the strongest one available.
There's a frustrating piece of history behind all this. When MDMA was made illegal, staff at the FDA actually argued it didn't belong in Schedule I, that the evidence pointed toward real medical value. The politics of the moment won out anyway, and it was scheduled at the most restrictive level. The cost of that choice was research itself, which got cut off almost entirely.